Entera Bio (ENTX) Gross Profit (2019 - 2024)

Entera Bio's (ENTX) quarterly Gross Profit came in at $9000.0 in Q2 2024, up 50.0% on a QoQ basis from $6000.0 in Q4 2022.

Entera Bio (ENTX) Gross Profit (2019 - 2024) Analysis & Trends

Entera Bio (ENTX) has 5 years of Gross Profit data on file, last reported at $9000.0 in Q2 2024.

Quarterly Gross Profit changed N/A year-over-year to $9000.0 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was $9000.0 (changed N/A YoY) and the FY2024 annual result came in at $9000.0, changed N/A from the prior year.
Gross Profit rose to $9000.0 in Q2 2024, from $6000.0 in the prior quarter.
In the past five years, Gross Profit ranged from a high of $84000.0 in Q1 2021 to a low of $2000.0 in Q3 2022.
A 4-year average of $26100.0 and a median of $12500.0 in 2022 frame the typical range for Gross Profit.
Annual changes were most pronounced in 2020 — Gross Profit jumped 75.0% — and 2022, when it tumbled 97.33%.
Tracing ENTX's Gross Profit over 4 years: stood at $21000.0 in 2020, then soared by 38.1% to $29000.0 in 2021, then sank by 79.31% to $6000.0 in 2022, then jumped by 50.0% to $9000.0 in 2024.
The last three Gross Profit figures came in at $9000.0 (Q2 2024), $6000.0 (Q4 2022), and $2000.0 (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Entera Bio	161.44 Mn	150.13 Mn	-

Download Data